成都先導(688222.SH)：擬收購Vernalis(R&D)Limited100%股權
格隆匯 10 月 12日丨成都先導(688222.SH)公佈，公司擬以自有資金或自籌資金，以2500萬美元的交易價格(該收購金額為假設目標公司無現金無負債的企業價值，最終交易金額需結合目標公司交割日報表的淨負債以及淨營運資本等確定)，通過全資子公司英國先導藥物有限公司(HITGEN UK LTD)為收購主體，受讓 LigandPharmaceuticals Incorporated通過VernalisLimited持有的Vernalis(R&D)Limited公司的100%股權。
此次收購的Vernalis公司在FBDD和SBDD的開發應用方面有着超過20年的經驗，並已成功開發和轉讓多項針對腫瘤、神經退行性疾病、抗感染和炎症等生物學目標的細胞活性先導化合物和臨牀階段候選物。Vernalis公司擁有一支超過70人的研發團隊，且團隊人員穩定，通過此次交易，成都先導能夠獲取Vernalis公司的核心技術團隊和知識產權。
目標公司的技術平台，能夠應用於化合物發現後的優化、化合物成藥性的評價，與成都先導自身的新藥開發平台相結合，有助於加速化合物向臨牀前研究、臨牀試驗、商業成果的轉化。
FBDD技術與DNA編碼化合物庫(DEL)技術存在很強的技術互補性，尤其在分子片段活性提升和先導化合物優化方面。此次收購可豐富和完善成都先導現有藥物發現技術、降低技術單一的風險。同時Vernalis公司在FBDD和SBDD的開發應用方面有着超過20年的經驗，其技術平台能夠應用於化合物發現後的優化、化合物成藥性的評價，與成都先導自身的新藥開發平台相結合，有助於加速化合物向臨牀前研究、臨牀試驗、商業成果的轉化。Vernalis公司擁有一支超過70人的研發團隊，且團隊人員穩定，通過此次交易，成都先導能夠獲取Vernalis公司的核心技術團隊和知識產權。英國劍橋是全球活躍的生物醫藥產業集羣之一，此次收購交易能夠使公司拓展海外研發和服務平台，增強與海外客户聯繫，促進與國際前沿生物醫藥技術的接軌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
